154 related articles for article (PubMed ID: 37730155)
1. HLADQA1∗05G>A Genetic Screening Promotes the Safe Delivery of Combination Therapy in Inflammatory Bowel Disease.
Wilson A; Chande N; Ponich T; Gregor JC; Choi YH; Kim RB
Clin Gastroenterol Hepatol; 2024 Apr; 22(4):890-892.e2. PubMed ID: 37730155
[No Abstract] [Full Text] [Related]
2. Decreased Infliximab Concentrations in Patients With Inflammatory Bowel Disease Who Carry a Variable Number Tandem Repeat Polymorphism in the Neonatal Fc Receptor or Variant HLADQA1*05G>A Genotype.
Choi B; Sey M; Ponich T; Beaton M; Kim R; Wilson A
Inflamm Bowel Dis; 2023 Mar; 29(3):437-443. PubMed ID: 36112504
[TBL] [Abstract][Full Text] [Related]
3. HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease.
Wilson A; Peel C; Wang Q; Pananos AD; Kim RB
Aliment Pharmacol Ther; 2020 Feb; 51(3):356-363. PubMed ID: 31650614
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment HLADQA1-HLADRB1 Testing for the Prevention of Azathioprine-Induced Pancreatitis in Inflammatory Bowel Disease: A Prospective Cohort Study.
Wilson A; Wang Q; Choi YH; Ponich T; Gregor JC; Chande N; Yan B; Sey M; Beaton M; Kim RB
Clin Transl Gastroenterol; 2021 Apr; 12(4):e00332. PubMed ID: 33821842
[TBL] [Abstract][Full Text] [Related]
5. Failure to Achieve Target Drug Concentrations During Induction and Not HLADQA1∗05 Carriage Is Associated With Antidrug Antibody Formation in Patients With Inflammatory Bowel Disease: Is HLADQA1∗05 Gone Before It's Here?
Wilson A; Kim RB
Gastroenterology; 2022 Oct; 163(4):1123-1124. PubMed ID: 35427575
[No Abstract] [Full Text] [Related]
6. Introduction: new approaches to the detection and management of inflammatory bowel disease: from genetic testing to treatment strategies.
Gassull MA; Obrador A
Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():1. PubMed ID: 16961736
[No Abstract] [Full Text] [Related]
7. New directions and new strategies in inflammatory bowel diseases.
Allez M; Lémann M
Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S121-2. PubMed ID: 20117334
[No Abstract] [Full Text] [Related]
8. Use of serologic markers as a screening tool in inflammatory bowel disease compared with elevated erythrocyte sedimentation rate and anemia.
Sabery N; Bass D
Pediatrics; 2007 Jan; 119(1):e193-9. PubMed ID: 17158948
[TBL] [Abstract][Full Text] [Related]
9. Effective Use of the Laboratory in the Management of Patients with Inflammatory Bowel Diseases.
Ince MN; Elliott DE
Gastroenterol Clin North Am; 2019 Jun; 48(2):237-258. PubMed ID: 31046973
[TBL] [Abstract][Full Text] [Related]
10. [APPROACH TO VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE].
Shpoliansky M; Shouval DS
Harefuah; 2020 Mar; 159(3):206-211. PubMed ID: 32186793
[TBL] [Abstract][Full Text] [Related]
11. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease.
Gisbert JP; McNicholl AG
Dig Liver Dis; 2009 Jan; 41(1):56-66. PubMed ID: 18602356
[TBL] [Abstract][Full Text] [Related]
12. Have genomic discoveries in inflammatory bowel disease translated into clinical progress?
Weizman AV; Silverberg MS
Curr Gastroenterol Rep; 2012 Apr; 14(2):139-45. PubMed ID: 22302508
[TBL] [Abstract][Full Text] [Related]
13. Scoring systems in inflammatory bowel disease.
Sehgal R; Koltun WA
Expert Rev Gastroenterol Hepatol; 2010 Aug; 4(4):513-21. PubMed ID: 20678023
[TBL] [Abstract][Full Text] [Related]
14. Clinical and laboratory predictors of monogenic very early onset inflammatory bowel disease.
Kelsen J; Dawany N; Conrad M; Patel T; Devoto M; Maurer K; Sullivan KE
Clin Immunol; 2022 Jul; 240():109047. PubMed ID: 35613698
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory bowel disease: Looking beyond the tract.
Chams S; Badran R; Sayegh SE; Chams N; Shams A; Hajj Hussein I
Int J Immunopathol Pharmacol; 2019; 33():2058738419866567. PubMed ID: 31382828
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory bowel disease in exclusively breast-fed infants.
Kuloğlu Z; Kansu A; Kirsaçlioğlu C; Ince E; Ensari A; Girgin N
Scand J Gastroenterol; 2006 Nov; 41(11):1364-7. PubMed ID: 17060132
[TBL] [Abstract][Full Text] [Related]
17. Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study.
Fuentes-Valenzuela E; García-Alonso FJ; Maroto-Martín C; Juan Casamayor L; Garrote JA; Almendros Muñoz R; De Prado Á; Vara Castrodeza A; Marinero MÁ; Calleja Carbajosa R; Barrio J
Inflamm Bowel Dis; 2023 Oct; 29(10):1586-1593. PubMed ID: 36617284
[TBL] [Abstract][Full Text] [Related]
18. Impact of exome sequencing in inflammatory bowel disease.
Cardinale CJ; Kelsen JR; Baldassano RN; Hakonarson H
World J Gastroenterol; 2013 Oct; 19(40):6721-9. PubMed ID: 24187447
[TBL] [Abstract][Full Text] [Related]
19. Attitudes toward genetic testing in patients with inflammatory bowel disease.
Lal S; Appelton J; Mascarenhas J; Stempak JM; Esplen MJ; Silverberg MS
Eur J Gastroenterol Hepatol; 2007 Apr; 19(4):321-7. PubMed ID: 17353697
[TBL] [Abstract][Full Text] [Related]
20. ACP Journal Club. Review: Calprotectin testing differentiates inflammatory bowel disease from the irritable bowel syndrome.
Moayyedi P
Ann Intern Med; 2014 Apr; 160(8):JC13. PubMed ID: 24733218
[No Abstract] [Full Text] [Related]
[Next] [New Search]
